AC
TGTX icon

Antara Capital’s TG Therapeutics TGTX Stock Holding History

Antara Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-900,000
Closed -$5.9M – 227
2022
Q2 		$3.83M Sell
900,000
-134,663
-13% -$841K 0.16% 109
2022
Q1 		$9.84M Buy
+1,034,663
New +$12M 0.3% 72
2021
Q4 		– Sell
-55,400
Closed -$1.44M – 256
2021
Q3 		$1.84M Buy
+55,400
New +$1.71M 0.14% 95

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Antara Capital's TGTX Position: Q3 2022 in Review

Antara Capital sold out of TG Therapeutics (TGTX) in Q3 2022, closing a stake of 900,000 shares — an estimated $5.9M sold.

Antara Capital first reported a position in TGTX in Q3 2021 and held it in 3 quarters. The position peaked at $9.84M in Q1 2022. 183 funds tracked by Wall St. Rank hold TGTX as of Q3 2022.

  • Antara Capital reported no remaining TG Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Antara Capital sold 900,000 TG Therapeutics shares in Q3 2022, an estimated $5.9M.
  • Antara Capital first reported a position in TG Therapeutics in Q3 2021 and held it in 3 quarters.
  • Antara Capital's TG Therapeutics position peaked at $9.84M in Q1 2022.
  • 183 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2022.

Based on Antara Capital's 13F filing for Q3 2022, filed 14 Nov 2022.